Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells Combined with Chemotherapy in EGFR-wild Type Lung Adenocarcinoma
NCT02621333Phase 2Terminated
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cytokine-induced killer cells in lung adenocarcinoma, sponsored by Henan Cancer Hospital. Started Oct 2015; status: terminated.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02621333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621333.